Elisa Muscianisi

发表

Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

U. Menchini, F. Bandello, M. Nicolò, 2015, Journal of ophthalmology.

Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.

G. Cimino, V. Carnovale, V. Lucidi, 2018, Respiratory medicine.

A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S).

Daniel B. Shin, A. Armstrong, T. Werner, 2020, The Journal of investigative dermatology.

Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease

V. Brusasco, L. Fabbri, A. Ungar, 2018, Expert review of respiratory medicine.

Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.

S. Nava, P. Schino, G. Catapano, 2018, Pulmonary pharmacology & therapeutics.

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

A. Gottlieb, M. Lebwohl, C. Griffiths, 2020, The Journal of dermatological treatment.

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

M. Lebwohl, A. Blauvelt, J. Bagel, 2018, Dermatology and Therapy.

Microdialysis assessment of peripheral metabolism in critical limb ischemia after endovascular revascularization

G. Piffaretti, M. Tozzi, P. Castelli, 2009, Annals of surgical innovation and research.

Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis

A. Blauvelt, D. Murrell, J. Krueger, 2020, Journal of Allergy and Clinical Immunology.

15340 Long-term treatment with secukinumab led to sustained clinical improvement and normalization of inflammatory markers in patients with psoriasis

A. Armstrong, F. Kianifard, A. Blauvelt, 2020 .

Narrative medicine to improve the management and quality of life of patients with COPD: the first experience applying parallel chart in Italy

M. Marini, P. Banfi, Elisa Muscianisi, 2018, International journal of chronic obstructive pulmonary disease.

Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study

F. Di Marco, S. Terraneo, P. Santus, 2017, npj Primary Care Respiratory Medicine.

Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase III Trials

A. Gottlieb, L. Uhlmann, G. Jemec, 2022, EMJ Dermatology.

Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis : Patient Symptom Diary Data from Two Phase 3 , Randomized , Placebo-controlled Clinical Trials

B. Elewski, G. Yosipovitch, J. Weiss, 2019 .

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

A. Gottlieb, L. Uhlmann, A. Kimball, 2023, The Lancet.

Secukinumab Provides Rapid Relief From Itching and Pain in Patients With Moderate-to-Severe Psoriasis: Patient Symptom Diary Data From Two Phase 3, Randomized, Placebo-Controlled Clinical Trials.

B. Elewski, G. Yosipovitch, J. Weiss, 2019, Acta dermato-venereologica.

Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.

F. Kianifard, A. Blauvelt, S. Tyring, 2023, Journal of dermatological science.